Sanofi announced on July 28th that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The...
LMC is looking for individuals with type 1 diabetes to participate in a research study involving an experimental insulin medication that may help lower meal-time glucose levels. Study related medication, supplies, and travel expenses may be provided. Speak with a...
LMC is looking for individuals with type 1 diabetes to participate in a research study involving an experimental insulin medication that may help lower meal-time glucose levels. Study related medication, supplies, and travel expenses may be provided. Speak with a...
Collaboration Brings Together Leading U.S. Metabolism-Focused CRO and Largest Canadian Diabetes Site Network SAN DIEGO AND TORONTO, June 10, 2016 /PRNewswire/ – Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused...
On March 10th, 2016, LMC will be holding a CME event discussing, “Common Pitfalls of Thyroid Disease Management in Primary Care”. This will be a historical event as this is the 1st time a PA (Physician Assistant) & their supervising physician are...
Toronto, February 1st, 2016 – LMC Diabetes & Endocrinology, the largest private Diabetes clinical research network in North America, announced their collaboration with Dr. Michael Riddell, PhD, a leading researcher in metabolic and hormonal responses to...
